Note: Ingredients listed on restricted chemical lists
EC/CAS
9003-39-8
Name of the chemical
polyvinylpyrrolidone
Concentration
N/A
EC/CAS
7732-18-5
Name of the chemical
Water, distilled, conductivity or of similar purity H2O
Concentration
N/A
EC/CAS
25322-68-3
Name of the chemical
polyethyleneglycol
Concentration
N/A
EC/CAS
231-791-2
Name of the chemical
Water, distilled, conductivity or of similar purity H2O
Concentration
N/A
General Information
Revision date
2015-02-11
Product name
PREDEF; PREDEF 2X
Icons in SDS
Company Information
company name
Zoetis Inc
e-mail address of the competent person responsible for the Safety Data Sheet
VMIPSrecords@zoetis.com
GHS Information
Signal word
Warning
Hazard Codes
Hazard statements (CLP)
H361d
Hazard statements
Code
Statements
H361d
Suspected of damaging the unborn child
Section 2
SECTION 2: Hazards identification
Appearance: Aqueous solution
2.1 Classification of the substance or mixture
Reproductive Toxicity: Category 2
EU Classification
EU Indication of danger: Not classified
Signal word
Warning
Hazard statements
H361d - Suspected of damaging the unborn child
Precautionary statements
P201 - Obtain special instructions before use P202 - Do not handle until all safety precautions have been read and understood P280 - Wear protective gloves/protective clothing/eye protection/face protection P308 + P313 - IF exposed or concerned: Get medical attention/advice P405 - Store locked up P501 - Dispose of contents/container in accordance with all local and national regulations
2.3 Other hazards
Short Term: No data available however, direct contact may cause eye irritation. Long Term: Due to its pharmacological action, exposure to this compound may produce adverse effects on fetal development. Known Clinical Effects: Clinical use may cause an increase in blood pressure (hypertension). Ingestion of this material may cause effects similar to those seen in clinical use including . gastrointestinal effects such as nausea, pain, heartburn, bleeding, ulceration, and perforation Clinical use has resulted in changes in electrolytes and/or blood chemistry changes. Drugs of this class may cause Cushing's syndrome, manifested by moon face, obesity, headache, acne, thirst, increased urination, impotence, menstrual irregularities, facial hair growth, and mental changes. Australian Hazard Classification
Hazardous Ingredients
Non-Dangerous Goods (NOHSC): Note: This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.
